# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Roth MKM analyst Jason Wittes reiterates Fortress Biotech (NASDAQ:FBIO) with a Buy and maintains $10 price target.
Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $(1....
Helocyte, a majority-owned subsidiary of Fortress Biotech, is developing Triplex for the prevention and treatment of cytomegalo...
Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(1....
Alliance Global Partners initiates coverage on Fortress Biotech (NASDAQ:FBIO) with a Buy rating and announces Price Target of...
Roth MKM analyst Jason Wittes reinstates Fortress Biotech (NASDAQ:FBIO) with a Buy and announces $10 price target.
Half of the enrolled patients had stable disease for at least two months, two showed partial response and two experienced com...